European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has formally approved a new perioperative treatment regimen involving its immune…
CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical manufacturing, with its state-of-the-art plasma processing facility in Broadmeadows, Victoria,…
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are poised to deliver a powerful presence at two of the…
Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada, announced a significant advancement in the treatment of platinum-resistant recurrent…
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into a definitive agreement to acquire efimosfermin alfa, a potential best-in-class…
FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Pheochromocytoma and Paraganglioma in Patients 12 Years and Older, Marking a New Era in Treatment of Rare Neuroendocrine Tumors Merck, known as MSD outside of the United States and Canada, has announced a…
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline, Novo Nordisk has entered into a landmark global collaboration and…
Sarepta’s ELEVIDYS Gene Therapy Gains Landmark Approval in Japan for Duchenne Muscular Dystrophy Sarepta Therapeutics, a biotechnology leader in precision genetic medicine for rare diseases, has announced a significant regulatory milestone: the Japanese Ministry of Health, Labour and Welfare (MHLW)…
UCB Highlights Robust Data on Generalized Myasthenia Gravis Therapies at 15th MGFA International Conference, Reinforcing Commitment to Patient-Centered Innovation UCB,a global biopharmaceutical leader specializing in immunology and neurology, has announced the presentation of a comprehensive suite of data from its…
Aetna, National Alliance for Care at Home, and MissionCare Collective Partner to Strengthen the Direct Care Workforce in Illinois, Louisiana, and North Carolina In a bold and strategic move to address critical workforce shortages in the home health care sector,…
Merck to Unveil Broad Range of Clinical Advances Across 25+ Cancer Types at ASCO 2025 Merck (NYSE: MRK), known as MSD outside the United States and Canada, is set to make a major impact at the upcoming 2025 American Society…
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful completion of a €132 million ($142 million USD equivalent) Series…